Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Free Cash Flow (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Free Cash Flow for 16 consecutive years, with -$2.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 30.78% to -$2.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$15.8 million, a 38.63% decrease, with the full-year FY2024 number at -$10.7 million, up 17.41% from a year prior.
  • Free Cash Flow was -$2.6 million for Q3 2025 at Plus Therapeutics, up from -$5.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$1.2 million in Q2 2024 to a low of -$6.2 million in Q1 2025.
  • A 5-year average of -$3.4 million and a median of -$2.9 million in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: soared 55.86% in 2024, then tumbled 371.57% in 2025.
  • Plus Therapeutics' Free Cash Flow stood at -$3.1 million in 2021, then grew by 23.56% to -$2.4 million in 2022, then grew by 18.59% to -$1.9 million in 2023, then skyrocketed by 34.06% to -$1.3 million in 2024, then plummeted by 101.66% to -$2.6 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Free Cash Flow are -$2.6 million (Q3 2025), -$5.8 million (Q2 2025), and -$6.2 million (Q1 2025).